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Abstract
Background: Pakistan is classified as one of the high multi-drug resistant tuberculosis (MDR-TB) burden countries.
A poorly regulated private sector, over-prescription of antibiotics and self-medication has led to augmented rates of
drug-resistance in the country. Pakistan’s first national anti-tuberculosis drug resistance survey identified high prevalence of fluoroquinolone resistance among MDR-TB patients. Further institutional evidence of fluoroquinolone drugresistance can support re-evaluation of treatment regimens as well as invigorate efforts to control antibiotic resistance
in the country.
Findings: In this study, data for drug-susceptibility testing (DST) was retrospectively analyzed for a total of 133
patients receiving MDR-TB treatment at the Chest Department of Jinnah Postgraduate Medical Center, Karachi,
Pakistan. Frequency analyses for resistance patterns was carried out and association of fluoroquinolone (ofloxacin)
resistance with demographics and past TB treatment category were assessed. Within first-line drugs, resistance to
isoniazid was detected in 97.7% of cases, followed by rifampicin (96.9%), pyrazinamide (86.4%), ethambutol (69.2%)
and streptomycin (64.6%). Within second-line drugs, ofloxacin resistance was detected in 34.6% of cases. Resistance
to ethionamide and amikacin was 2.3% and 1.6%, respectively. Combined resistance of oflaxacin and isoniazid was
detected in 33.9% of cases. Age, gender and past TB treatment category were not significantly associated with resistance to ofloxacin.
Conclusion: Fluoroquinolone resistance was observed in an alarmingly high proportion of MDR-TB cases. Our results
suggest caution in their use for empirical management of MDR-TB cases and recommended treatment regimens for
MDR-TB may require re-evaluation. Greater engagement of private providers and stringent pharmacy regulations are
urgently required.
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Findings
Background

Globally, emerging drug resistance poses a serious threat
to the control of tuberculosis (TB) [1]. In 2012, the World
Health Organization (WHO) estimated 450,000 (range
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300,000–600,000) new cases of multidrug-resistant TB
(MDR-TB) in the world; 3.6% of newly diagnosed TB
cases, causing an estimated 170,000 (range 102,000–
142,000) deaths [2]. Pakistan contributes to 69% of the
MDR-TB burden in the Eastern Mediterranean Region
(EMRO), with an estimated 11,000–29,000 cases occurring in 2012 [2]. Over the past few years the country has
also reported an increasing trend of Extensively Drug
Resistance disease (XDR-TB) that includes resistance
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to fluoroquinolones and at least one other second-line
injectable, in addition to MDR-TB [3].
Fluoroquinolone resistance is of particular public
health importance as it is a widely prescribed antibiotic
for treatment of common respiratory tract infections.
There is a rampant and poorly regulated private healthcare sector in Pakistan, where over-prescription of fluoroquinolones by general practitioners, over-the-counter
sales at private pharmacies and self-medication by
patients occur commonly [4]. Recently published findings
from the first national anti-tuberculosis drug resistance
survey of Pakistan identified fluoroquinolone resistance
of 26.6% (95% CI 18.0–36.7) among a total sample of 96
MDR-TB cases [5]. Evidence suggests that occurrence
of fluoroquinolone resistance is on the rise, with a study
reporting increase in its prevalence from 17.4% in 2005,
to 53.9% in 2014 among MDR-TB patients [6].
Fluoroquinolones are the mainstay of treatment of
MDR-TB and resistance has been associated with poor
treatment outcomes for MDR-TB patients [6]. Rising fluoroquinolone resistance is, therefore, of serious
concern for the management of MDR-TB patients, particularly at a time when Pakistan is scaling-up its Programmatic Management of Drug-resistant TB (PMDT)
program [7]. Scale-up of Xpert MTB/RIF testing in the
country has significantly facilitated diagnosis of MDR-TB
since resistance to rifampicin can be identified at the time
of diagnosis [8]. However, patients initially require empirical treatment as drug-susceptibility testing (DST) results
to fluoroquinolones and other second-line drugs require
6–8 weeks by conventional methods. A lack of clinical
response to medication can be alarming for both patients
and providers [9]. In the setting of increasing resistance
to fluoroquinolones, current combinations of empirical
therapy used by MDR-TB programs may require revaluation. Further institutional evidence of fluoroquinolone
drug-resistance among MDR-TB patients can support
such recommendations as well as boost efforts to control
antibiotic resistance in the country. This study describes
the drug-resistance patterns of microbial isolates from
MDR-TB suspects from a tertiary-care facility in Karachi,
Pakistan from 2009 to 2012.
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carried out at the Aga Khan University clinical laboratory, a technical partnering facility for the National TB
Program (NTP). Demographic and clinical histories of
the patients were obtained from the hospital records.
Treatment history was categorized as prior history of
Category I TB treatment (four-drug anti-TB treatment
regimen) and Category II (four-drug anti-TB treatment
regimen + streptomycin). Frequency analyses for resistance patterns and demographic variables were carried
out. The association of ofloxacin (a second-generation
fluoroquinolone) resistance with age was investigated
using Student’s t test. Chi squared tests were conducted
to investigate the association of ofloxacin resistance with
gender and treatment history. Statistical analyses were
carried out using Stata/IC 12.0 (Stata Corp, College Station, TX, USA).
Results

A total of 133 patients receiving MDR-TB treatment were
included in the study. Median age of the patients was 16
(IQR 10–26) and 51.1% were male (Table 1).
Within first-line drugs, resistance to isoniazid was
reported in 97.7% of cases followed by rifampicin (96.9%),
pyrazinamide (86.4%), ethambutol (69.2%) and streptomycin (64.6%) (Table 2).
Within second-line drugs, ofloxacin resistance was
observed in 34.6% of cases. Resistance to ethionamide
and amikacin was 2.3 and 1.6%, respectively (Table 2).
Combined resistance to ofloxacin and isoniazid was
reported in 33.9% of cases (Table 2). Ofloxacin resistance
was more commonly observed in patients with history
of Category I treatment (54.3%) compared to Category
II (40.7%), however, the difference was not statistically
significant (p value 0.26). Age (p value 0.92) and gender (p value 0.85) were not significantly associated with
ofloxacin resistance. A total of 3 cases were found to have
XDR-TB.
Table 1 Demographic characteristics of MDR-TB patients
at Jinnah Postgraduate Medical Center, Karachi, Pakistan
(2009–2012)
n

Methods

We analyzed de-identified, retrospective data of patients
receiving MDR-TB treatment at Jinnah Postgraduate Medical Center, the largest public-sector hospital in
Pakistan’s southern Sind province, between 2009 and
2012. All patients enrolled on MDR-TB program had a
history of TB treatment and were included in the analysis using convenience sampling. Sputum was obtained
from the patients prior to MDR-TB treatment initiation
and DST of Mycobacterium tuberculosis isolates was

(%)

Age (years)
9–14

10

(8)

15–29

71

(54)

30–44

33

(25)

45<

19

(14)

Male

68

(51.1)

Female

65

(48.9)

Gender

Total

133
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Table 2 Resistance to first and second-line anti-tuberculous medication among MDR-TB patients at Jinnah Postgraduate Medical Center, Karachi, Pakistan (2009–2012)
Number of cases
with resistance
n

(%)

Isoniazid (H)

130

(97.7)

Rifampicin (R)

129

(96.9)

Pyrazinamide (Z)

115

(86.4)

Ethambutol (E)

92

(69.2)

Streptomycin (S)

86

(64.6)

Kanamycin (Km)

1

(0.8)

Amikacin (Am)

2

(1.5)

Capreomycin (Cm)

2

(1.5)

49

(34.6)

Ethionamide (Eto)

3

(2.3)

Cycloserine (Cs)

1

(0.8)

Any resistance (first line drugs)

Any resistance (second line drugs)

Ofloxacin (Ofx)

Combined resistance of H with other drugs
H+Z
H+E

H+S

H+Z+E

H+Z+E+S

H + Ofx

114

(85.7)

91

(68.4)

86

(64.7)

90

(67.7)

67

(50.4)

45

(33.9)

Discussion

Our results support findings from previously reported
studies and the national anti-TB drug resistance survey,
highlighting growing resistance to fluoroquinolones in
Pakistan. This is the first study describing institutional
evidence from an MDR-TB treatment facility of the high
prevalence of fluoroquinolone resistance among MDR-TB
cases. Resistance was not associated with age, gender or
history of TB treatment, suggesting that resistance may be
widespread within this patient population. These findings
raise concerns for the outcomes of MDR-TB patients and
for empirical treatment, following rifampicin resistance
identification through an Xpert MTB/RIF assay. Recommended treatment regimens for MDR-TB may therefore
require revaluation for improved treatment outcomes and
to curtail development of further drug-resistance.
Given the above scenario, several public health policy
measures and programmatic interventions can be of
benefit. Firstly, the use of antibiotics, particularly fluoroquinolones needs to be strongly regulated. This is likely
to be a major challenge, given Pakistan’s large and fragmented private healthcare sector. A regulation restricting over-the-counter sale of antibiotics also needs to be
introduced, the practical implementation of which could

be difficult. Secondly, strategies to engage with the private-sector providers more comprehensively need to be
explored. Recent initiatives proposed by the National
TB Control program are encouraging [10]. Under novel
public–private mix approaches, local networks and partnerships can be created where private providers receive
medication through provincial TB control programs for
patients and in turn, help to increase case-notification.
Greater efforts should be in place to collaborate with
general practitioners, especially with family practitioners operating in small clinics in urban areas. Trainings
should be conducted on NTP guidelines for TB casedetection and treatment as well as on more judicious use
of antibiotics for treatment of common infections, with
a special emphasis on restricting use of fluoroquinolones. Medical associations, including those representing
infectious disease specialists, pulmonologists as well as
pharmacists need to be play a more active role in communicating this message to providers and to the public.
Finally, MDR-TB programs will require greater efforts to
improve case-holding and ensuring treatment completion for enrolled patients, as PMDT services expand in
the country. Community-based solutions and behavioral
economics approaches such as the use of food-baskets
and other incentives for treatment compliance may be
of benefit [11]. Early case-detection through scale-up of
Xpert MTB/RIF testing may help improve treatment outcomes as well as limit transmission of resistant strains.
This study was limited by the absence of DST results for
third and fourth generation fluoroquinolones for assessing cross-resistance with ofloxacin of M. tuberculosis isolates. In addition, limited patient history was available,
such as prior history of quinolone use, to further investigate risk factors and clinical correlates to fluoroquinolone
resistance. We recommend further studies to evaluate
MDR-TB treatment outcomes and their association with
fluoroquinolone resistance among DR-TB patients.
Conclusions

Fluoroquinolone resistance was observed in an alarmingly high proportion of MDR-TB cases. Our results
suggest caution in their use for empirical management
of MDR-TB cases (particularly second-generation) and
therefore recommended treatment regimens for MDRTB may require revaluation. Engaging private sector
providers in TB case-detection and stringent pharmacy
regulations are required to prevent increased resistance
to fluoroquinolones in Pakistan.
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